Skip to main content
SINSIN PHARMACEUTICAL Co., LTD. logo

SINSIN PHARMACEUTICAL Co., LTD. — Investor Relations & Filings

Ticker · 002800 ISIN · KR7002800001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2023-03-15 Audit Report / Informat…
Country KR South Korea
Listing KO 002800

About SINSIN PHARMACEUTICAL Co., LTD.

https://sinsin2002.tradekorea.com/

Sinsin Pharmaceutical Co., Ltd. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of over-the-counter (OTC) medicines for external use. The company's core product portfolio centers on topical anti-inflammatory and analgesic drugs, including its widely recognized brand of pain relief patches, "SINSIN PAS," alongside various sprays and lotions. The company also produces a diverse range of consumer healthcare items such as mosquito repellents, wound care products like surgical plasters and healing bands, anti-mycotic treatments, and other dermatological preparations for both domestic and overseas markets.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by ShinShin Pharmaceutical. It contains the auditor's opinion (적정 - Unqualified), financial highlights (assets, liabilities, revenue, profit/loss), and details regarding the audit firm (신한회계법인). While it provides financial data, it is a regulatory filing summarizing the audit results rather than the full Annual Report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings (DART/KIND), this specific format is classified as a regulatory filing announcement regarding the audit report. FY 2022
2023-03-15 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Sinsin Pharmaceutical Co., Ltd. for the 60th fiscal year (2022). It contains comprehensive financial statements, management discussion and analysis, governance information, and audit details. As it is a full-year comprehensive financial report, it is classified as an Annual Report (10-K). FY 2022
2023-03-15 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Sinsin Pharmaceutical Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), information on board activities, and financial statements (balance sheets and income statements) to be approved at the meeting. This is a standard proxy statement/notice of meeting document provided to shareholders to inform them of the upcoming AGM and solicit their votes.
2023-03-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to provide shareholders with information regarding upcoming general meetings and to solicit their votes. It contains details about the meeting agenda, director candidates, and financial summaries, fitting the definition of a Proxy Solicitation & Information Statement.
2023-03-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for insider transactions (directors or major shareholders buying/selling shares). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2023-02-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Shinshin Pharmaceutical. It outlines the date, location, and agenda items (financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and request their participation/votes.
2023-02-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.